ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Psychiatry

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

14,496Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 62

$1.25M Total Retail Price of All Prescriptions

Rank: 2 out of 62

413 Patients Receiving at Least One Drug in Part D
8%Patients 65 Years and Older
96% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Hampshire
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 413 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

N/A

Risky Drugs to Seniors

9% of this provider’s 1,123 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

16% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$86 was the average price of a prescription from this provider, compared to $122 among peers.

Prescriptions per Patient

35 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Hampshire
RISPERIDONE 1,094 147 1 4
TRAZODONE HCL 832 38 2 1
BENZTROPINE MESYLATE 793 52 R 3 13
FLUOXETINE HCL 723 52 4 6
QUETIAPINE FUMARATE 721 38 5 3
DIVALPROEX SODIUM 570 30 6 21
BUSPIRONE HCL 516 88 7 20
CITALOPRAM HBR 487 18 8 8
LAMOTRIGINE 435 12 9 9
OLANZAPINE 425 136 10 5
SERTRALINE HCL 383 29 11 11
ABILIFY 375 20 12 7
GABAPENTIN 360 73 13 22
CLOZAPINE 328 36 14 2
FLUPHENAZINE HCL 303 0 15 42
BUPROPION HCL SR 295 19 16 19
ZIPRASIDONE HCL 292 40 17 28
LITHIUM CARBONATE 283 0 18 12
PAROXETINE HCL 279 0 19 24
PROPRANOLOL HCL 272 0 20 33
SEROQUEL 271 0 21 23
AMITRIPTYLINE HCL 222 0 R 22 38
ESCITALOPRAM OXALATE 216 0 23 25
SEROQUEL XR 212 54 24 26
MIRTAZAPINE 206 25 25 16
HALOPERIDOL 192 0 26 29
DIVALPROEX SODIUM ER 182 0 27 18
CYMBALTA 170 0 28 15
TOPIRAMATE 159 0 29 35
RISPERDAL CONSTA 150 32 30 27
ZOLPIDEM TARTRATE 142 0 31 10
NALTREXONE HCL 132 0 10 32 52
PERPHENAZINE 125 0 33 36
OLANZAPINE ODT 125 0 33 43
VENLAFAXINE HCL ER 112 0 35 14
BUPROPION XL 105 0 36 17
CHLORPROMAZINE HCL 105 0 36 51
INVEGA 101 0 38 49
CARBAMAZEPINE 96 0 39 41
LOVAZA 94 0 40 59
FLUPHENAZINE DECANOATE 89 0 41 70
GEODON 79 0 42 73
HYDROXYZINE PAMOATE 79 0 R 42 32
INVEGA SUSTENNA 73 0 44 39
ZYPREXA 71 34 45 48
CLONIDINE HCL 64 24 46 40
TRIHEXYPHENIDYL HCL 58 54 R 47 81
FLUVOXAMINE MALEATE 55 0 48 53
OMEPRAZOLE 55 0 48 60
RIVASTIGMINE 53 0 50 62
LEXAPRO 52 0 51 58
NORTRIPTYLINE HCL 50 0 52 54
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.